艾斯拓康

Aistokang is a clinical-stage biotechnology company based in Suzhou, China, dedicated to the discovery and development of innovative small molecule therapeutics for metabolic and chronic diseases. The company's primary focus is on addressing significant unmet medical needs in non-alcoholic steatohepatitis (NASH), obesity, and type 2 diabetes. Its lead candidate, AST-001, is a highly selective thyroid hormone receptor beta (THR-β) agonist currently undergoing Phase 2 clinical trials for the treatment of NASH. Aistokang also advances a pipeline of oral small molecule GLP-1 receptor agonists designed to offer improved patient convenience and efficacy. By leveraging its proprietary drug discovery platform and deep expertise in metabolic pathways, the company aims to deliver best-in-class treatments for global markets.